These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8507260)

  • 1. Risk factors for acute graft-versus-host disease associated with cyclosporine and methotrexate prophylaxis.
    Russell N; Rogers S; Hunter A
    Blood; 1993 Apr; 81(7):1972-4. PubMed ID: 8507260
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
    Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
    Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease.
    Gondo H; Harada M; Taniguchi S; Akashi K; Hayashi S; Teshima T; Takamatsu Y; Eto T; Nagafuji K; Yamasaki K
    Bone Marrow Transplant; 1993 Nov; 12(5):437-41. PubMed ID: 8298553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral and nutritional status in allogeneic marrow recipients treated with T-cell depletion or cyclosporine combined with methotrexate to prevent graft-versus-host disease.
    Mattsson T; Heimdahl A; Dahllöf G; Lönnquist B; Ringdén O
    Oral Surg Oral Med Oral Pathol; 1992 Jul; 74(1):34-40. PubMed ID: 1508507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.
    Storb R; Deeg HJ; Whitehead J; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Doney K; Farewell V
    N Engl J Med; 1986 Mar; 314(12):729-35. PubMed ID: 3513012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
    Törlén J; Ringdén O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itälä-Remes M; Remberger M; Mattsson J
    Haematologica; 2016 Nov; 101(11):1417-1425. PubMed ID: 27662016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.
    Yerushalmi R; Shem-Tov N; Danylesko I; Shouval R; Nagler A; Shimoni A
    Am J Hematol; 2017 Mar; 92(3):259-268. PubMed ID: 28052467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whether methotrexate administration in graft-versus-host disease prophylaxis significantly delays the engraftment in allogeneic peripheral blood progenitor cell transplantation.
    Urbano-Ispizua A; Carreras E; Sierra J; Rovira M; Rozman C
    Blood; 1995 Jul; 86(2):836-7. PubMed ID: 7606019
    [No Abstract]   [Full Text] [Related]  

  • 9. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation.
    Tseng LH; Lin MT; Hansen JA; Gooley T; Pei J; Smith AG; Martin EG; Petersdorf EW; Martin PJ
    Blood; 1999 Oct; 94(8):2911-4. PubMed ID: 10515896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
    Chao NJ; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM
    N Engl J Med; 1993 Oct; 329(17):1225-30. PubMed ID: 8413388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
    Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
    Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited tolerance of intensified conditioning regimens in children receiving methotrexate/cyclosporin A for graft-versus-host disease prophylaxis.
    Emminger W; Emminger-Schmidmeier W; Peters C; Hawliczek R; Höcker P; Gadner H
    Pediatr Hematol Oncol; 1992; 9(1):1-9. PubMed ID: 1558771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis.
    Ruutu T; Nihtinen A; Niittyvuopio R; Juvonen E; Volin L
    Cancer; 2018 Feb; 124(4):727-733. PubMed ID: 29112242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease.
    Storb R; Deeg HJ; Farewell V; Doney K; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Hansen J
    Blood; 1986 Jul; 68(1):119-25. PubMed ID: 3521761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation.
    Yee GC; Self SG; McGuire TR; Carlin J; Sanders JE; Deeg HJ
    N Engl J Med; 1988 Jul; 319(2):65-70. PubMed ID: 3288872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.
    Wagner JE; Thompson JS; Carter SL; Kernan NA;
    Lancet; 2005 Aug 27-Sep 2; 366(9487):733-41. PubMed ID: 16125590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft-versus-host disease prophylaxis.
    Loughran TP; Deeg HJ; Dahlberg S; Kennedy MS; Storb R; Thomas ED
    Br J Haematol; 1985 Mar; 59(3):547-53. PubMed ID: 3882141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study.
    Ruutu T; Volin L; Parkkali T; Juvonen E; Elonen E
    Blood; 2000 Oct; 96(7):2391-8. PubMed ID: 11001889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival.
    Ross M; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM; Smith EP; Snyder DS; Stein AS; Wong RM; Forman SJ; Blume KG; Chao NJ
    Biol Blood Marrow Transplant; 1999; 5(5):285-91. PubMed ID: 10534058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.